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MaBACKGROUND Papillary ﬁbroelastomas (PFE) are benign neoplasms with little available outcome data.
OBJECTIVES This study sought to describe the frequency and clinical course of patients with surgically removed PFE
and echocardiographically suspected, but unoperated, PFE.
METHODS Mayo Clinic pathology and echocardiography databases (January 1, 1995, to December 31, 2010) were
queried, resulting in 511 patients: group 1 (n ¼ 185), including patients with surgically removed, histopathologically
conﬁrmed PFE; group 1a (n ¼ 94; 51%) with PFE removed at primary surgery; and group 1b (n ¼ 91; 49%) with PFE
removal at time of another cardiac surgery. Group 2 (n ¼ 326) patients had echocardiographic evidence of PFE but no
cardiac surgery to remove PFE.
RESULTS Group 1 had mean age of 63  14 years (116 women [63%]). During the study period, we identiﬁed 112 cardiac
myxomas in the pathology database and 142 in the echocardiographic database. Mean age in group 2 was 67  14 years
(162 women [50%]). PFE occurred most commonly on cardiac valves (n ¼ 400 [78%]). In group 1, transient ischemic
attack or stroke was the presenting symptom in 58 patients (32%). With surgical removal of valvular PFE, the valve was
preserved in 92 (98%). Recurrence was documented in 3 patients (1.6%). Follow-up stroke risk in groups 1, 1a, and 1b at 1
year was 2%, 0%, and 4%; at 5 years, 8%, 5%, and 11%, respectively. Cerebrovascular accident risk in group 2 at 1 and
5 years was 6% and 13%.
CONCLUSIONS In patients with echocardiographically suspected PFE who do not undergo surgical removal, rates of
cerebrovascular accident and mortality are increased. (J Am Coll Cardiol 2015;65:2420–9) © 2015 by the American
College of Cardiology Foundation.C ardiac papillary ﬁbroelastomas (PFE) aresmall, benign endocardial lesions that areclinically important because of their docu-
mented embolic potential. Although generally consid-
ered a common benign cardiac tumor, they are not the
most common. In 1 autopsy series (1), PFE were the
third most frequently occurring cardiac tumor, behind
cardiac myxoma and lipoma. Histologically, PFE are
avascular structures composed of ﬁbroelastic tissue
surrounded by endocardium, imparting a charac-
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2421echocardiography where the patient did not un-
dergo excision.SEE PAGE 2430
CI = conﬁdence interval
CVA = cerebrovascular
accident
HR = hazard ratio
IQR = interquartile range
NE = neurologic event(s)
PFE = papillary
ﬁbroelastoma(s)
RR = relative risk
TEE = transesophageal
echocardiography
TIA = transient ischemic attack
TTE = transthoracic
echocardiographyMETHODS
This study was approved by the Mayo Clinic Institu-
tional Review Board. The pathology and echocardi-
ography databases of Mayo Clinic (Rochester,
Minnesota) were queried for cases of PFE and cardiac
myxoma occurring between January 1, 1995, and
December 31, 2010, for retrospective review. Inclu-
sion and exclusion criteria were applied (Figure 1).
Patients were excluded from the study if any of the
following was present:
 Patient declined access to their records for
research.
 Inﬂammatory or infectious disease was present at
time of incident PFE (n ¼ 224).FIGURE 1 Study Flowchart
Group 1 (from pathology database): 185 patients
Total 917 patients scre
10 excluded on surgical in
33 excluded on histopath
18 excluded on echo review 
G
This chart outlines the inclusion and exclusion criteria for this study. CM
TEE ¼ transesophageal echocardiography. Transesophageal echocardiography (TEE)
did not conﬁrm ﬁndings of PFE suspected
on transthoracic echocardiography (TTE)
(n ¼ 30) or, on review of images, PFE was
not conﬁrmed (n ¼ 18).
 Surgeon could not conﬁrm PFE or
echocardiography-identiﬁed mass at sur-
gery (n ¼ 10) or histopathologic evaluation
did not support the diagnosis (n ¼ 33)
(Table 1).
Patients were separated into 2 groups.
Group 1 met histopathologic criteria for diag-
nosis of PFE. This group was divided into
group 1a, including patients for whomPFEwas
the primary reason for surgical intervention,
and group 1b, including patients forwhomPFE
excision was not the primary indication for surgery.
Group 2 met echocardiographic criteria for PFE.
Histopathologic diagnosis was rendered by a car-
diovascular pathologist (J.J.M. or W.D.E.) based59  overlap with group 1
643 patients
224 had historical exclusions
30 excluded on TEE
1 excluded on CMR
419 patients
389 patients
379 patients
378 patients
344 patients
326 patients included
ened
spection
ology
by authors
roup 2 (from echo database): 702 patients
R ¼ cardiac magnetic resonance imaging; echo ¼ echocardiography;
TABLE 1 Histopathologic Exclusions (N ¼ 33)*
Degenerative or ﬁbrocalciﬁc disease 11 (32)
Lambl excrescence 9 (26)
Myxoma 3 (9)
Hemangioma 3 (9)
Nonbacterial thrombotic endocarditis 2 (6)
Rheumatic valvular disease 1 (3)
Lipoma 1 (3)
Infective endocarditis 1 (3)
Thrombus 1 1 (3)
Libman-Sacks endocarditis 1 (3)
Values are n (%). *After echocardiographic diagnosis of papillary ﬁbroelastoma.
TABLE 2 Baseline Clinical Characteristics
Group 1
(n ¼ 185)
Group 2
(n ¼ 326) p Value
Female 116 (63) 162 (50) 0.45
Age, yrs 63  14 67  14 0.002
CVA 23 (12) 79 (24) 0.001
TIA 35 (19) 42 (13) 0.07
Chest pain 31 (17) 36 (11) 0.08
Valvular dysfunction of PFE valve 22 (12) 29 (9) 0.29
Previous radiation 7 (4) 28 (9) 0.04
Atrial ﬁbrillation 49 (26) 99 (30) 0.36
Hypertension 80 (43) 200 (61) <0.001
Diabetes mellitus 32 (17) 90 (28) 0.02
Previous rheumatic heart disease 20 (11) 15 (5) 0.009
Previous cardiac surgery 20 (11) 45 (14) 0.41
Coronary angiogram performed 138 (75) 53 (16) <0.001
Previous IE 6 (3) 0 (0) 0.002
Immunosuppression 3 (2) 18 (6) 0.04
Values are n (%) or mean  SD.
CVA ¼ cerebrovascular accident; IE ¼ infective endocarditis; PFE ¼ papillary
ﬁbroelastoma; TIA ¼ transient ischemic attack.
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2422on presence of branching endocardium-lined fronds
containing an avascular ﬁbroelastic core. To assess
the relative frequency of PFE, we queried institu-
tional pathology databases for the incidence of car-
diac myxoma during the study period.
To identify patients with echocardiographic evi-
dence of PFE, we queried the Echocardiography and
Hemodynamic Laboratory database to identify all
patients with the echocardiography diagnosis PFE.
Echocardiograms were reviewed using previously
published echocardiographic characteristics of PFE
(3,4): a small mobile mass attached to an endocardial
surface, with independent motion and a stippled or
shimmering border (especially notable under high
resolution or by TEE). These were speciﬁcally distin-
guished from Lambl excrescences, which are linear
echocardiographic densities.
Follow-up data for stroke, peripheral embolism,
and death were obtained from the medical records.
STATISTICAL ANALYSIS. Continuous variables were
summarized as mean  SD or median (interquartile
range [IQR]), as appropriate. These variables were
compared between groups using a 2-sample test or
nonparametric Wilcoxon rank sum test. Categorical
variables were summarized as counts and percent-
ages and compared between groups using the Pearson
chi-square test.
Time-to-event outcomes were deﬁned as time from
index date to event for those with events and last
known follow-up for those without events. The
Kaplan-Meier method was used to describe event
rates at time points of interest, and event rates were
compared between groups using the log-rank test.
Observed events in these patients were compared
with published rates (5), age- and sex-matched, and
compared with the 1-sample log-rank test.
To examine the association of baseline variables
with outcomes, Cox proportional hazards regression
models were used. The results of these models weresummarized with hazard ratio (HR) and 95% con-
ﬁdence intervals (CIs). As a secondary analysis
to compare mortality between patients with and
without surgery, a propensity-based approach was
used. The propensity of having surgery was estimated
on the basis of variables in Table 2 in addition to
New York Heart Association class and size of PFE.
Patients were then grouped by quartiles of propensity
score (area under the curve: 0.77), and Cox regres-
sion was used to estimate the effect of surgery within
each stratum. These estimates were combined for
presentation using a weighted average approach
(6). Statistical analysis was performed using JMP
(SAS Institute, Inc., Cary, North Carolina) and SAS
(version 9.3, SAS Institute). Statistical signiﬁcance
was set at p # 0.05, and 2-sided tests were used for all
analyses.
RESULTS
During the study period, 575,772 unique patients un-
derwent echocardiography at Mayo Clinic. After ex-
clusions, the study group contained 511 patients
(mean age: 66  14 years; 60% women), representing
0.089% of all patients undergoing echocardiography
during the 16 years. Patient characteristics in group 1
(n ¼ 185) and group 2 (n ¼ 326) are shown in Table 2.
In both groups, PFE most commonly occurred on
valves — aortic (n ¼ 304 [59%]), mitral (n ¼ 64 [13%]),
tricuspid (n ¼ 23 [4%]), and pulmonary (n ¼ 9 [2%]) —
with the remainder (n ¼ 111 [22%]) on nonvalvular
endocardial surfaces. During this period, 112 his-
topathologically conﬁrmed cardiac myxomas were
TABLE 3 Indications for Echocardiography
Group 1
(n ¼ 185)
Group 2
(n ¼ 326) p Value
Murmur or valvular heart disease 51 (28) 42 (13) <0.001
NE* 45 (24) 107 (33) 0.04
Hypertrophic cardiomyopathy 26 (14) 16 (5) <0.001
Chest pain or CAD 24 (13) 36 (11) 0.57
Atrial ﬁbrillation 6 (3) 39 (12) <0.001
Heart failure symptoms 5 (3) 23 (7) 0.04
Values are n (%). *Includes CVA and TIA.
CAD ¼ coronary artery disease; NE ¼ neurologic event; other abbreviations as in
Table 2.
FIGURE 2 Group 1: PFE Size
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2423identiﬁed in the pathology database and 142 in the
echo database.
ECHOCARDIOGRAPHIC FINDINGS. Patients in group
1 had a mean age at diagnosis of 63  14 years; 116
were women (63%). Most were initially identiﬁed
with echocardiography (n ¼ 152 [82%]). PFE diagnosis
was made by preoperative echocardiography in 119
patients (64%), intraoperative TEE in 33 (18%), sur-
gical inspection in 12 (7%), and gross or histopatho-
logic evaluation alone in 19 (10%). In the 98 patients
with both TTE and TEE, PFE could be seen only by
TEE in 32 (33%) and on both TTE and TEE in 50 (51%).
Indications for echocardiography are shown in
Table 3. Group 1 had more structural heart disease
(p < 0.001); group 2 had more atrial ﬁbrillation (p <
0.001) and neurologic events (NE) (including transient
ischemic attack [TIA], stroke, or both) (p ¼ 0.045).
PFE location and size are shown in Figure 2. In
group 1, mean PFE size was 9.76  5.94 mm (IQR: 6 to
12 mm) by echocardiography, which was larger than
in group 2 (7.57  3.30 mm; IQR: 5 to 10 mm) (p <
0.001). In groups 1 and 2 combined, 183 patients had a
previous NE (Table 4). Group 2 had more patients
presenting with a history of NE than group 1 did (58
[32%] vs. 125 [38%]; p ¼ 0.045). Group 2 had more NE
as indication for echocardiography (107 [33%] vs. 45
[24%]; p ¼ 0.04). In both groups, patients with an NE
as a presenting symptom had signiﬁcantly smaller
PFE at diagnosis (7.13  4.21 mm; IQR: 4 to 8.5 mm)
than those who presented with other indications
(8.95  4.43 mm; IQR: 6 to 10 mm) (p < 0.001).
In group 1, the PFE was valvular in 153 patients. The
predominant location was the aortic valve in 96
(63%), followed by left atrium or ventricle in 24 (16%),
mitral valve in 14 (9%), tricuspid valve in 9 (6%), right
atrium or ventricle in 9 (6%), and pulmonary valve in
1 (<1%). In 126 patients (82%), there was no functional
valvular abnormality, but 23 (15%) had at least mod-
erate dysfunction likely due to underlying valvedisease (not to the PFE), including rheumatic disease
(n ¼ 6), myxomatous mitral valve disease (n ¼ 5),
previous heart surgery (n ¼ 4), and post-inﬂammatory
valve disease (n ¼ 4), and 1 patient each with degen-
erative valve disease, congenital heart disease, pul-
monary hypertension, and aortic root dilation. Only
1 patient had mild-moderate regurgitation with no
obvious valvular abnormality other than PFE. Thirty-
eight patients (21%) had multiple PFE (range 2 to 40).
The valvular PFE in group 2 had only mild valvular
stenosis or regurgitation in 300 patients (92%). Forty-
four patients (14%) had more than 1 PFE. An attempt
was made to determine predictive features of PFE.
Echocardiographic characteristics of the PFE were not
signiﬁcantly associated with a cerebrovascular acci-
dent (CVA): size (RR: 1.04; 95% CI: 0.94 to 1.16;
p ¼ 0.41), mobility (RR: 0.96; 95% CI: 0.52 to 1.78;
p ¼ 0.89), and aortic valvular location (RR: 1.26; 95%
CI: 0.58 to 2.77; p ¼ 0.56).
In 18 patients of group 1, PFE was diagnosed on
pathologic inspection alone: 6 (33%) on excised aortic
valves; 4 (22%) on left ventricular outﬂow tract
endocardium; 3 (17%) on excised mitral valves; 2
(11%) on excised tricuspid valves; and 1 each (6%) on
the right ventricular outﬂow tract endocardium, the
left atrium, and a pacemaker lead. In this group, 8
(44%) had congenital heart disease, 6 (33%) rheu-
matic heart disease, 2 (11%) degenerative ﬁbrocalciﬁc
aortic valve disease and hypertrophic cardiomyopa-
thy, 1 (6%) myxomatous mitral valve disease, and 1
(6%) PFE was on the pacemaker lead. These patients
were all in group 1b.
Compared with group 1b, group 1a patients had
more NE, more chest pain, and signiﬁcantly more
TABLE 4 PFE Size in Patients Presenting With and Without NE
IQR, mm Median, mm Minimum, mm Maximum, mm Mean  SD
Group 1
With 5-10 7 3 37 8.49  5.92
Without 6.5-13.5 9 1 40 10.39  5.88
Group 2
With 4-8 6 2 16 6.52  3.03
Without 6-10 8 2.5 20 8.21  3.31
IQR ¼ interquartile range; other abbreviations as in Tables 2 and 3.
TABLE 5 Symptoms in Group 1a and 1b Patients
Group 1a*
(n ¼ 94)
Group 1b†
(n ¼ 91) p Value
NE 43 (46) 15 (16) <0.001
CVA 18 (19) 5 (5) 0.006
TIA 25 (27) 10 (11) 0.008
Chest pain 10 (11) 21 (23) 0.03
NYHA functional class I 74 (79) 20 (22) <0.001
Systemic emboli 3 (3) 5 (5) 0.49
Syncope 10 (11) 11 (12) 0.82
Values are n (%). *Patients who had surgery for PFE as a primary indication.
†Patients who had other indications for surgery.
NYHA ¼ New York Heart Association; other abbreviations as in Tables 2 and 3.
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2424were in New York Heart Association class I (Table 5) at
diagnosis, but ages were similar (p ¼ 0.16).
GROUP 1 FOLLOW-UP. Median post-operative clinical
follow-upwas 1.6years (IQR:0.3 to4.2years), including
echocardiography in 122 patients (66%) at a median of
2.9 years (IQR: 0.9 to 5.3 years). Recurrent PFE was
documented in 3 patients (1.6%). In group 1a (n ¼ 94),
the native valve was preserved in 92 patients (98%).
One patient required an aortic valve replacement at the
time of surgery because the valve could not be repaired
after the PFE excision and another patient had an
attemptedaorticvalve repair at the timeofPFE removal
that later failed, necessitating valve replacement.
In group 1, overall risk of CVA was 2% at 1 year and
8% at 5 years (p ¼ 0.003) (Table 6). Ten CVA were
recorded during follow-up compared with 4.1 ex-
pected CVA based on age- and sex-matched rates. In
group 1a, risk of CVA was 0% at 1 year and 5% at 5
years (p ¼0.81), with 2 CVA recorded in follow-up (1.7
expected CVA). In group 1b, risk of CVA was 4% at 1
year, 11% at 5 years (p < 0.001); 8 CVA were recorded
in follow-up versus 2.4 expected.
For group 1, 30-day survival was 99% (100% for
group 1a and 96% for group 1b). In group 1a, median
survival was 9.4 years. At 1 year and 5 years, 95% and
86% of patients, respectively, were alive, compared
with 94% and 86% in group 1b who had surgery for
other indications (p ¼ 0.32, log-rank test) and also had
a PFE excised (Figure 3).
GROUP 2 FOLLOW-UP. Follow-up was available in
317 patients (97%), median length 1.7 years (IQR: 0.2
to 4.8 years). At 1 and 5 years, the risk of CVA was
6% and 13%, respectively, and 99% and 98% were
without clinical features of peripheral embolism.
There were 29 CVA during follow-up versus 8.4 CVA
expected (p < 0.001). The risk of CVA compared with
the age- and sex-matched rates is outlined in Figure 4.
Fifty-four patients (17%) were referred for, but did
not ultimately undergo, surgery. Observed survival
compared with age- and sex-matched rates (Figure 5)
was signiﬁcantly decreased (p < 0.001).Only 8 patients in group 2 did not also have other
risk factors for embolic events (e.g., atherosclerosis,
atrial ﬁbrillation, systemic hypertension).
Of 121 patients in group 2 with a history of NE,
anticoagulant medications were taken by 87 (72%) at
the time of PFE diagnosis. These therapies included
warfarin in 27 (22%), aspirin in 57 (47%), clopidogrel
in 1 (1%), and dual antiplatelet therapy in 2 (2%).
There was no signiﬁcant difference in the occurrence
of subsequent stroke between patients treated with
warfarin or antiplatelet drugs versus those not taking
medication. The 5-year rates of freedom from CVA
in patients taking warfarin, aspirin, or clopidogrel
(alone or with aspirin) were 86%, 87%, and 91%,
respectively, which was not signiﬁcantly different
from those not taking medication (p ¼ 0.39).
COMPARISON OF GROUPS 1 AND 2. One- and 5-year
survival rates were 98% and 84% for group 1 and
87% and 67% for group 2 (p ¼ 0.02, log-rank test).
HRs were estimated using Cox proportional hazards
regression to compare groups, and with age adjust-
ment, the HR for group 1 versus group 2 was 0.67
(95% CI: 0.44 to 0.97; p ¼ 0.03). A similar HR was
estimated in the propensity stratiﬁcation approach
(HR: 0.68; p ¼ 0.08). In group 1a at 1 year and 5 years,
95% and 86% of patients were alive compared with
94% and 84% in group 1b (p ¼ 0.32, log-rank test).
These groups also had similar survival after age
adjustment (p ¼ 0.57).
A difference in mortality was observed between
group 1a and group 2 (HR: 0.51; 95% CI: 0.29 to 0.92;
p ¼ 0.02) but not between group 1b and group 2 (HR:
0.69; 95% CI: 0.43 to 1.10; p ¼ 0.12) (Figure 3). How-
ever, with age adjustment, similar results were ob-
served for comparison among groups: Group 1a versus
group 2 (HR: 0.54; 95% CI: 0.30 to 0.99; p ¼ 0.05) and
group 1b versus group 2 (HR: 0.71; 95% CI: 0.44 to
1.15; p ¼ 0.16). The estimated difference in mortality
between group 1a and group 2 remained similar in the
TABLE 6 Observed* Versus Expected† CVA Rates
Patients Follow-Up, yrs
CVA Rate/1-yr
Follow-Up (%)
CVA Rate/5-yr
Follow-Up (%)
Observed
Events (n)
Expected
Events (n)
Observed vs. Expected
Events p Value
Group 1 185/511 (36) 1.6 (0.3-4.2) 2 8 10 4.1 0.003
Group 1a 94/185 (51) 0.7 (0.1-4.2) 0 5 2 1.7 0.81
Group 1b 91/185 (49) 2.7 (0.5-5.5) 4 11 8 2.4 <0.001
Group 2 326/511 (64) 1.7 (0.2-4.8) 6 13 29 8.4 <0.001
Values are n/N (%) or median (IQR) unless otherwise indicated. *Rates observed in study sample. †Rates expected based on age- and sex-matched control subjects.
Abbreviations as in Tables 2, 3, and 4.
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2425propensity-based analyses, but it was no longer sig-
niﬁcant (HR: 0.61; p ¼ 0.10). Observed rates for sur-
vival and CVA in group 2 were compared with
published rates matched for age and sex; the
observed rates were higher than expected for both
endpoints (p < 0.001) (Figures 4 and 5).
DISCUSSION
This study was undertaken to describe PFE fre-
quency, clinical importance, and characteristics. To
our knowledge, this is the largest series of patients
with PFE, with follow-up in both operated and
unoperated patients. We reached 5 important con-
clusions from this work.
First, PFE is more common than cardiac myxoma,
at a rate of approximately 2:1, for a rate of 1 PFE
per every 1,100 echocardiograms in our referral
base population. Assuming these lesions are indeed
neoplastic, this rate makes them the most common
benign primary cardiac neoplasms of adulthood.
Additionally, a signiﬁcant association exists be-
tween clinically diagnosed PFE and NE. Both mor-
tality and risk of subsequent CVA are greater in
patients with PFE identiﬁed with echocardiography
and not removed than with age- and sex-matched
rates. The risk of CVA is 6% at 1 year and 13% at
5 years.
PFE cannot be stratiﬁed into high- and low-risk
types based on echocardiographic characteristics.
PFE can be safely excised with preservation of the
native valve in experienced surgical centers. Long-
term results are excellent in patients undergoing
primary excision.
Finally, recurrence of a PFE after removal develops
in 1.6% of patients and holds potential implications
for follow-up.
FREQUENCY OF PFE. Initially, there appears to be a
temporal increase in PFE diagnosis from 0.019% with
the original 1997 report from our institution (3) to
0.089% seen here. However, multiple reasons may
account for this rise, including increasing use of
echocardiography, better technology with improvedresolution, enhanced awareness of PFE, and an aging
population. A less likely reason: an actual increase in
PFE incidence.
Cardiac myxomas are widely recognized as the most
common primary benign cardiac neoplasms of adult-
hood, but most of the supporting data were derived
from an autopsy series (1,2). During the study time
frame, we identiﬁed 112 pathologically conﬁrmed car-
diac myxomas at our institution, compared with 185
PFE. This suggests that PFE, rather than cardiac myx-
oma, is the most common benign cardiac neoplasm of
adulthood, assuming PFE is indeed a neoplastic (and
not reactive or hamartomatous) lesion.
CLINICAL FINDINGS. Two previously published
studies have implications in comparison with our
study. We conﬁrmed several observations and were
concordant with the ﬁndings of Sun et al. (4): PFE
most commonly arose on valves, though not infre-
quently on nonvalvular endocardial surfaces (22%),
and relatively small lesions (<1 cm) did not cause
valvular dysfunction. Compared with a meta-analysis
by Gowda et al. (7), our study had signiﬁcantly more
women (p ¼ 0.001). All studies showed a direct cor-
relation of PFE incidence with age: mean age was in
the sixth decade in the study by Sun et al. (4), the
seventh decade in the present study, and a peak
incidence in the eighth decade in the meta-analysis
(7). These data suggest that although PFE can be
seen at any age, the risk increases with age.
All 3 studies suggest an association of PFE with
thromboembolic events. The incidence of a present-
ing NE reported in the previous studies was 17% (7)
and 13% (4). In our study, the indication for echo-
cardiography was NE in 32% of group 1 (CVA: 13%;
TIA: 19%) and 36% in group 2 (CVA: 24%; TIA: 13%).
Follow-up in group 2 revealed an 8.9% incidence of
new CVA. Unlike previous landmark studies, ours is
the ﬁrst to show the incremental risk of PFE on sub-
sequent CVA above baseline risk, which in unoper-
ated PFE was 6% at 1 year and 13% at 5 years, which
are higher than age- and sex-matched rates.
Sun et al. (4) found that the incidence of CVA
or TIA in 45 patients was 6.6% when monitored for
FIGURE 5 Expected Versus Observed Survival
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In group 2 patients, survival decreased signiﬁcantly compared to
age- and sex-matched control subjects (p < 0.001).
FIGURE 3 Group 2 Survival Compared With Subgroups 1a and 1b
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Over time, survival in group 2 patients (who did not undergo surgery) stabilized more than
that seen in patients in subgroup 1a (surgery for papillary ﬁbroelastoma removal only) or
subgroup 1b (surgery for another indication with incidental papillary ﬁbroelastoma
removal) patients. Values shown below the graph represent unadjusted Kaplan-Meier
survival estimates (number of subjects at risk) at 1, 3, 5, and 10 years.
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diagnosis of PFE. The present study’s ﬁndings are
similar: group 2 had a CVA incidence of 6% at 1 year
(p ¼ 0.78). Of note, 33% of group 2’s patients had
already had a TIA or CVA or both, and they were older
than the group in Sun et al. (4) (67  15 years vs. 58 
16 years).
Indeed, even in group 1 after PFE excision, a small
risk of CVA persisted, likely reﬂecting the background
risk of CVA in this patient population, per age group
(5,8). In group 1a, where the main reason for surgery
was PFE removal, post-operative CVA risk was notFIGURE 4 Expected Versus Observed CVA
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The occurrence of cerebrovascular accidence (CVA) that was
observed in group 2 patients was lower than expected compared
with age- and sex-matched control subjects (p < 0.001).greater than expected (p ¼ 0.81), whereas in group 1b,
where the patient population was sicker at the time of
surgical intervention, it is not surprising that CVA risk
was higher than expected (p < 0.001). Some of this
risk may be due to recurrent PFE, and this notion
requires further investigation. In the past, our group
has suggested that endocardial injury (e.g., surgery)
may predispose to PFE (3,9).
In these published studies, treatment was deter-
mined by the managing clinician and the patient.
Thus, the decision to have the PFE surgically excised
was inﬂuenced by perceived risk versus beneﬁt. The
analysis by Gowda et al. (7) determined that PFE
mobility was the only characteristic predictive of
embolism. In our model, we identiﬁed no single
echocardiographic characteristic predictive of such
risk.
A previous surgical series by Ngaage et al. (10)
compared patients in whom PFE was the primary
indication for surgery to those in whom PFE was an
incidental surgical ﬁnding. This led us to look at
group 1 in the distinct subgroups of group 1a and
group 1b. Both the present study and the one by
Ngaage et al. (10) showed the high success rate of
shave resection, sparing the valve.
ECHOCARDIOGRAPHIC CHARACTERISTICS AND
DIAGNOSIS OF PFE. The overall incidence of PFE in
patients referred for echocardiography was 0.089%.
Of note, 47% of the total study group had both TTE
and TEE, 27% had TEE only, and 17% had TTE only; it
is possible that if TEE were done for all patients, PFE
incidence might be higher. Our PFE size range, from 2
to 40 mm, is smaller than reported in the meta-
analysis by Gowda et al. (7) but similar to that of
Sun et al. (4). Although the location and distribution
of the PFE in our study are concordant with those
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valve PFE (64% vs. 45% (4) and 31% (7)). The next
most likely location is the mitral valve, followed in
decreasing frequency by cardiac chambers, tricuspid
valve, and pulmonary valve. Similar to the study by
Sun et al. (4), we found PFE in left-sided chambers to
be signiﬁcantly larger than those on left-sided valves
(p ¼ 0.005). In accord with previous studies, we
found that the PFE were not typically thought to
cause valvular dysfunction.
The indications for diagnostic echocardiography
were signiﬁcantly different between groups 1 and 2.
More patients in group 1 had structural heart disease,
whereas more patients in group 2 had an NE, atrial
ﬁbrillation, or heart failure. Nonvalvular PFE oc-
curred more frequently in the left-sided chambers.
Right-sided PFE were signiﬁcantly larger than left-
sided, possibly because right-sided lesions are less
clinically apparent and manifest later. An almost
equal proportion of PFE arose from the aortic and
ventricular surfaces of the aortic valve; this varies
from 2 previous studies where the former (4) and
latter (10) predominated.
Approximately one-quarter of all patients in both
groups had PFE detected on TEE but not TTE, rein-
forcing TEE’s importance when investigating embolic
phenomena. There were 34 patients who had PFE
suggested from echocardiography, but the lesion
proved to represent something else histologically
(Table 1). This underscores that echocardiography can
suggest, but cannot ultimately make, the diagnosis.
This ﬁnding also highlights the need for echocardiog-
raphers to be familiar with PFE characteristics.
Almost one-ﬁfth of group 1 had their PFE unexpectedly
diagnosed during surgery with intraoperative TEE
surveillance, which is routinely used in most cardio-
vascular surgical cases in our institution, highlighting
the utility of such evaluation. The majority of PFE
missed on TEE were detected in the setting of a serious
operation for underlying cardiac disease. A previous
meta-analysis (7) reported that most PFE were
discovered incidentally in patients being evaluated for
CVA,which is similar towhatwe found. Themost likely
reason PFE might not have been detected on TTE but
was seen on TEE is lesion size.
FOLLOW-UP. The incidence of 1.6% for echocardio-
graphically detected, post-operative recurrence of
PFE has not been reported previously (4,7,10). These
recurrences were diagnosed at 1, 5, and 6 years after
the original excision. PFE are thought to be either
neoplastic, hamartomatous, or reactive lesions. New
PFE may arise at or near the site of previous resection
due to endocardial injury, but also they may arise
from lesional cells left behind during incompleteresection. The surgeon may be able to tell patients
that the PFE was grossly removed, but cannot tell
them that another PFE will not develop in the future
near that site or elsewhere in the heart. We had 1
patient who had undergone a subaortic septal myec-
tomy with a single PFE excised and then had more
than 40 PFE removed from the same site many years
later (9). Her surgeon described the ventricle as
looking like a shag carpet.
In group 1a, which had PFE excision as a solitary
procedure, post-operative survival and 1-year sur-
vival were 100%, and 1-year freedom from CVA was
100%. At 5 years, there were 2 CVA, no evidence of
recurrence, and no residual valvular regurgitation.
Two patients needed aortic valve replacement. Group
1b contained patients with serious cardiac disease
requiring surgical intervention. Thus, it was a sicker
group than group 1a was and, not surprisingly, had a
different post-operative outcome. In group 2, 8.9% of
patients had a subsequent CVA. No identiﬁable
echocardiography characteristic of the PFE was
signiﬁcantly associated with CVA. We therefore could
not deﬁne high- or low-risk characteristics of PFE,
unlike in the study by Gowda et al. (7), wherein
characteristics of mobility and aortic location were
associated with increased risk of embolism. Their
observation may be due to greater sample size.
This is the ﬁrst report of event-free and overall
survival in unoperated PFE patients. In group 2, pa-
tients had higher incidences of CVA and death than
expected based on age- and sex-matched rates, and
CVA risk was 6% at 1 year and 13% at 5 years. Patients
in group 2 were older and had more traditional risk
factors for CVA than did group 1, yet the risk of CVA
and death held up in age-adjusted modeling and the
incidence of risk factors was similar to the general
population when adjusted for age. This information
may be useful when counseling patients who have an
incidental PFE on echocardiography but no other
abnormality necessitating surgery.
PFE MANAGEMENT. In group 2, 55 patients (17%) did
not undergo PFE excision despite the managing
physician’s recommendation. The risk-to-beneﬁt ra-
tio of cardiac surgery was likely inﬂuenced by older
age, comorbid conditions, and perhaps the uncer-
tainty of embolic risk. In some referral cases, the pa-
tient declined surgery even though the surgeon was
prepared to operate. This study adds to the current
literature by quantifying the risk of PFE and its as-
sociation with CVA in follow-up compared with
background risk.
The study may not have the power to evaluate the
beneﬁt of anticoagulation, antiplatelet therapy, or
dual antiplatelet therapy. Nevertheless, we did not
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subsequent CVA among patients treated with such
agents.
The increased occurrence of CVA in patients with
PFE, despite comorbid conditions, is also a novel
ﬁnding. We have found previous observations in
studies by Sun et al. (4) and Gowda et al. (7) to be
complementary to our present observations and
expand current understanding through the follow-up
comparison with age- and sex-matched rates.
At our tertiary referral center, we recommend that
patients who are good surgical candidates (Society
of Thoracic Surgeons score <1%) with left-sided
PFE (regardless of size, mobility, or location) consider
surgical excision. We base this recommendation onCENTRAL ILLUSTRATION Management Scheme for Suspe
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For patients with suspected papillary ﬁbroelastoma (PFE), this decision-
echo ¼ echocardiography; LA ¼ left atrium; SBE ¼ subacute bacterial enour practice’s excellent outcomes, the data sug-
gesting that excision substantially decreases CVA
risk from PFE, and the fact that the valve can usually
(98%) be spared when excision is the primary surgical
indication (Central Illustration). Clearly, institutional
surgical expertise factors importantly in treatment
decisionmaking. Advances such as robotic approaches
may further improve outcomes (11).
When a patient is not a surgical candidate or re-
fuses surgery, we have been recommending long-
term treatment with antiplatelet agents. Because
supporting data are limited, we base this on the his-
tologic observation that surface thrombi may occur.
Importantly, this is an echocardiography-based
study. Although a PFE has classic echocardiographycted PFE
Consider Antiplatelet Agent
ART 
nd With Echo
nding diagnoses:
olipid antibodies
Not a Surgical Candidate
Increased risk of removal
Aspirin treatment
PFE
Ao
LA
 managing cardiologist
reference
t
making tree reviews management options. Ao ¼ aorta;
docarditis; SLE ¼ systemic lupus erythematosus.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: PFE should be
considered in the differential diagnosis of source of embolism
work-up. This study is the ﬁrst large single-center review of the
management of a relatively rare benign cardiac neoplasm. It
suggests that PFE should be considered for removal in patients
with low surgical risk.
TRANSLATIONAL OUTLOOK: Further clinical trials are
needed to verify whether removal prevents central neurological
events (CVA and TIA) and mortality, to deﬁne the optimal pa-
tients for surgical removal, and to determine whether medical
management with antiplatelet or anticoagulation will improve
outcomes, especially in patients who are not candidates for
surgical intervention or who decline surgical intervention.
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nosis but instead provide only a differential diagnosis
of the mass (3,4,7). We advise that patients have
blood cultures, antiphospholipid antibodies, and be
screened for lupus.
STUDY LIMITATIONS. The current study is limited
primarily by its retrospective nature and the inherent
issues with follow-up in this type of study. It is also
important to note the referral bias of our tertiary care
center. The propensity-based approach, though an
effective way to control for potential confounders,
results in loss of power because of stratiﬁcation into
quartiles.
CONCLUSIONS
This large, single-center study conﬁrms that PFE
most commonly occur on cardiac valves, although
they may be found on any endocardial surface. Al-
though PFE were usually small, patients not under-
going surgery face increased risk of stroke and
mortality. Surgical excision is effective, with a high
likelihood of valve preservation and low recurrence
rate when performed at a high-volume tertiary care
center. However, recommendations for an aggressive
surgical approach need to be placed in context of the
local surgical expertise. Although this is the currentapproach at our institution, management may best be
sorted out ultimately with a randomized trial.
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